Compare Kaltura Inc (KLTR) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kaltura Inc vs Mesoblast Limited — how do they compare? Kaltura Inc trades at $1.37 (market cap $208.27M), while Mesoblast Limited trades at $16.36 (market cap $2.17B). The key difference: Mesoblast Limited is far larger — about 10.4× Kaltura Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, Kaltura Inc nearer its low. Which is the better fit depends on your goals.
| KLTR | MESO | |
|---|---|---|
Market Cap | $208.27M | $2.17B |
Sector | Technology | Technology |
52-Week High | $1.97 | $20.96 |
52-Week Low | $1.08 | $12.88 |
Enterprise Value | $190.99M | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kaltura (KLTR) trades at $1.385, down 0.36% with a bullish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and revenue stabilizing around $180M. Recent industry recognition includes being named a Leader in virtual event platforms by Forrester and Aragon Research in June 2026. Operating cash flow turned positive in Q1 2026 for the first time in company history, though net margins remain negative at -8.25%.
While technical indicators suggest near-term strength, fundamental challenges persist with negative ROE of -107.84% and high P/B ratio of 44.85. Analyst consensus leans bullish with 44% buy ratings, but profitability concerns and competitive pressures in the digital experience platform space warrant caution. The upcoming Q2 2026 earnings on August 5 will be critical for validating the company's turnaround trajectory.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kaltura Inc
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments: (i) Enterprise, Education, and Technology (EE&T)
Read more on KLTR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
